Humira is a human monoclonal antibody that works by blocking tumor necrosis factor alpha (TNF-alpha). The side effects are usually mild, but serious side effects can occur.

The 40 mg/0.8 mL pre-filled Cyltezo Pen will be available in two-, four- and six-pack options on July 1, 2023. The Cyltezo Pen features a one-button, three-step activation, with 100% drug ...

The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. ADRIAN FLORIDO, HOST: ...

"By the end of 2023, Humira's annual net price decreased to $29,800, a 38% drop compared with $48,000 1 year prior, likely due to biosimilar competition," they acknowledged.

Coherus BioSciences and Mark Cuban’s Cost Plus Drug Company will shake up the Humira and Humira-referenced biosimilar space with the launch of Yusimry at a 85% discount.

AbbVie's signature drug is Humira, which now faces biosimilar competition. (David J. Phillip / The Associated Press) Seven new alternatives to the high-cost Humira drug will be available in July.

A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira By Juliana M. Reed Reprints David J. Phillip/AP ...

Analysts predict that sales of Humira will fall to $14.1 billion this year, before dropping to $8.7 billion in 2024 and $6.1 billion the following year, according to Refinitiv data.

SYDNEY LUPKIN, BYLINE: Humira is an injectable drug approved in 2002 that treats a range of illnesses, including Crohn's disease and rheumatoid arthritis. The drug is popular with patients but has ...